[go: up one dir, main page]

EE04961B1 - N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis - Google Patents

N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis

Info

Publication number
EE04961B1
EE04961B1 EEP200100447A EEP200100447A EE04961B1 EE 04961 B1 EE04961 B1 EE 04961B1 EE P200100447 A EEP200100447 A EE P200100447A EE P200100447 A EEP200100447 A EE P200100447A EE 04961 B1 EE04961 B1 EE 04961B1
Authority
EE
Estonia
Prior art keywords
insulin resistance
propoxy
pyridine
oxide
methods
Prior art date
Application number
EEP200100447A
Other languages
English (en)
Estonian (et)
Inventor
βria K�rthy M
B�r� Katalin
βroly Nagy K
βszl� �r�gdi L
Cs βkai Zita
Szilbereky Jen�
βs Mogyor�si Tam
T�r�k Magdolna
βs Kom βromi Andr
M βrv βnyos Ede
βly Barab βs Mih
βlyn� Kardos Mih
βn Nagy Zolt
βszl� Kor βnyi L
Nagy Melinda
Original Assignee
Biorex Kutat� �s Fejleszto Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutat� �s Fejleszto Rt. filed Critical Biorex Kutat� �s Fejleszto Rt.
Publication of EE200100447A publication Critical patent/EE200100447A/xx
Publication of EE04961B1 publication Critical patent/EE04961B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200100447A 1999-02-26 2000-02-24 N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis EE04961B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (2)

Publication Number Publication Date
EE200100447A EE200100447A (et) 2002-12-16
EE04961B1 true EE04961B1 (et) 2008-02-15

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100447A EE04961B1 (et) 1999-02-26 2000-02-24 N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis

Country Status (27)

Country Link
US (1) US6649628B1 (xx)
EP (1) EP1163224B1 (xx)
JP (1) JP4689838B2 (xx)
KR (1) KR100676124B1 (xx)
AT (1) ATE237590T1 (xx)
AU (1) AU779096B2 (xx)
BG (1) BG65178B1 (xx)
BR (1) BR0008969A (xx)
CA (1) CA2360451C (xx)
CZ (1) CZ297386B6 (xx)
DE (1) DE60002187T2 (xx)
DK (1) DK1163224T3 (xx)
EE (1) EE04961B1 (xx)
ES (1) ES2193055T3 (xx)
HR (1) HRP20010584B1 (xx)
HU (1) HUP9900475D0 (xx)
IL (2) IL144866A0 (xx)
NO (1) NO319793B1 (xx)
PL (1) PL197692B1 (xx)
PT (1) PT1163224E (xx)
RS (1) RS50083B (xx)
RU (1) RU2250901C2 (xx)
SI (1) SI1163224T1 (xx)
SK (1) SK287063B6 (xx)
UA (1) UA72495C2 (xx)
WO (1) WO2000050403A1 (xx)
ZA (1) ZA200106488B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
MXPA04006716A (es) * 2002-01-11 2004-11-10 Biorex Kutato Es Rejleszt Rt Derivados de carboxamidina y su uso en el tratamiento de enfermedades vasculares.
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
DK2318032T3 (da) 2008-06-26 2012-06-11 Orphazyme Aps Anvendelse af Hsp70 som regulator af enzymatisk aktivitet
WO2010058779A1 (ja) 2008-11-18 2010-05-27 参天製薬株式会社 ピリジン-3-カルバルデヒド o-(ピペリジン-1-イル-プロピル)-オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
NZ706356A (en) * 2012-09-06 2018-02-23 Mcpharma Biotech Inc Treatment of diarrhea and post-weaning diarrhea with resistant potato starch
CA2884777C (en) 2012-09-14 2018-02-27 Saint-Gobain Glass France Pane with an electrical connection element
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
CN107106494B (zh) * 2014-09-15 2021-12-21 奥菲泽米有限公司 阿瑞洛莫制剂
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
HRP20210047T1 (hr) 2016-04-29 2021-04-16 Orphazyme A/S, c/o COBIS A/S Arimoclomol za liječenje poremećaja povezanih s glukocerebrozidazom
BR112019024667A2 (pt) 2017-05-24 2020-06-16 Orphazyme A/S Uso de um agente bioativo, e, de uma composição
AU2019276048B2 (en) 2018-05-28 2025-09-04 Zevra Denmark A/S Hsp70 protein levels in PBMC samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
IL299250A (en) 2020-06-24 2023-02-01 Kempharm Denmark As Arimoclomol for the treatment of Gaucher disease
CN116783164A (zh) * 2020-11-19 2023-09-19 泽维拉丹麦股份有限公司 制备柠檬酸阿瑞洛莫及其中间体的方法
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
MX2023007551A (es) 2020-12-24 2023-09-04 Zevra Denmark As Arimoclomol para el tratamiento de la enfermedad de niemann pick, tipo c, en pacientes con mutaciones de sentido erroneo de tipo reticulo endoplasmatico (er).

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
ZA200106488B (en) 2002-08-07
HUP9900475D0 (en) 1999-04-28
CZ20013053A3 (cs) 2002-01-16
SI1163224T1 (en) 2003-08-31
KR20010102410A (ko) 2001-11-15
CA2360451A1 (en) 2000-08-31
DK1163224T3 (da) 2003-08-04
PT1163224E (pt) 2003-07-31
ATE237590T1 (de) 2003-05-15
UA72495C2 (uk) 2005-03-15
YU60301A (sh) 2004-05-12
IL144866A0 (en) 2002-06-30
NO319793B1 (no) 2005-09-12
ES2193055T3 (es) 2003-11-01
SK287063B6 (sk) 2009-10-07
RS50083B (sr) 2009-01-22
PL350915A1 (en) 2003-02-10
DE60002187D1 (de) 2003-05-22
HRP20010584B1 (en) 2010-08-31
IL144866A (en) 2007-07-04
NO20014103D0 (no) 2001-08-23
HRP20010584A2 (en) 2002-08-31
SK11582001A3 (sk) 2001-12-03
EP1163224B1 (en) 2003-04-16
EP1163224A1 (en) 2001-12-19
CA2360451C (en) 2011-01-04
WO2000050403A1 (en) 2000-08-31
PL197692B1 (pl) 2008-04-30
BG65178B1 (bg) 2007-05-31
EE200100447A (et) 2002-12-16
RU2250901C2 (ru) 2005-04-27
BR0008969A (pt) 2001-11-27
JP2002537384A (ja) 2002-11-05
JP4689838B2 (ja) 2011-05-25
DE60002187T2 (de) 2003-12-11
BG105837A (en) 2002-03-29
US6649628B1 (en) 2003-11-18
AU779096B2 (en) 2005-01-06
AU3182400A (en) 2000-09-14
NO20014103L (no) 2001-10-22
KR100676124B1 (ko) 2007-01-31
CZ297386B6 (cs) 2006-11-15

Similar Documents

Publication Publication Date Title
EE04961B1 (et) N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis
GB0223038D0 (en) Therapeutic compounds
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
TW229205B (xx)
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
DE60035232D1 (de) (S,S)-Reboxetine zur Behandlung von chronischen Erschöpfungssyndrom
CY1106409T1 (el) Παραγωγα κινολινης
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
SE0102147D0 (sv) New methods
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
MXPA05013121A (es) Derivados de indol con efecto de induccion de apoptosis.
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
TW200503999A (en) Therapeutic agents
BR9609932A (pt) Uso de derivados de prostano e a combinação dos mesmos com antibióticos no tratamento das infecções bacterianas
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
TW200716083A (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
DE60224078D1 (de) Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
MXPA05014081A (es) Derivados de benzofurano y su uso en el tratamiento de infecciones microbianas.
EP1908462A3 (en) Dichloroacetate in combination with cardioprotective or hemodynamic drugs

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110224